Results from Recent Pivotal Trials in Prostate Cancer - Cora Sternberg

Cora Sternberg joins Alicia Morgans in a discussion on practice transforming presentations in prostate cancer from the 2019 GU ASCO meeting. Among the presentations overviewed is the ARAMIS trial in nonmetastatic castration-resistant prostate cancer (mnCRPC) where Cora highlights its similarities to the PROSPER and SPARTAN trials. They discuss progression-free survival in the second update on the...

Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky

Matthew Galsky and Alicia Morgans share in a discussion on combination and maintenance strategies for muscle-invasive and metastatic bladder cancer and a number of reasons for combining immunotherapy with immune checkpoint blockade. These reasons include the concept of immunogenic cell death, depletion of suppressive immune cell subsets and independent drug action. Biographies: Matthew Galsky, MD,...

Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial - Dena Battle

President of KCCure, Dena Battle joins Monty Pal in a discussion on the management of de novo metastatic kidney cancer and the change in practice from cytoreductive nephrectomy to an option of systemic therapy driven by the results of CARMENA trial. Dena shares the patients perspective on this treatment paradigm which comes from a patient survey her organization put forth answering the question of...

Darolutamide Demonstrates Efficacy and Safety in Men with nmCRPC - Neeraj Agarwal

Petros Grivas discussed Neeraj Agarwal's insights about the latest prostate cancer study results that will impact patient care as presented at ASCO GU 2019. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under develop...

Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman

Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer. Michael Hofman details the quick advance of PSMA imaging in Australia. He highlights PSMA tracers including Gallium-68 and PSMA-Based [18F]DCFPyL PET/CT and th...

Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo

Alicia Morgans interviews Andrea Apolo who details the trial design and current status of the Phase III adjuvant AMBASSADOR trial for patients with high-risk muscle-invasive bladder cancer (MIBC) and the need to develop additional treatment options for patients who are resistant to chemotherapy and develop recurrent disease. The AMBASSADOR trial aims to answer the question if there is a benefit to...

Prostate Cancer Disparities in the VA Health System - Megan McNamara

Colleagues Megan McNamara and Dan George discuss the paradox findings of a retrospective study evaluating the differences in survival of mCRPC patients from in the VA system. Despite having the highest incidence of prostate cancer compared with all other racial groups, as well as a higher risk of prostate cancer mortality, African Americans were found to have longer survival when treated with abir...

Immunotherapy Across Genitourinary Malignancies - James Gulley

In this interview, James Gulley recaps the Keynote Lecture he gave at the GU ASCO 2019 annual symposium discussing immunotherapy across genitourinary malignancies and the different advancements in prostate, kidney and bladder cancer. Biographies: James L. Gulley, MD, PhD, Chief Genitourinary Malignancies, Director, Clinical Trials Group and of the Medical Oncology Service, Office of the Clinical D...

ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC - Karim Fizazi

Karim Fizazi details two presentation he gave at the ASCO GU 2019 meeting. The first is the ARAMIS trial that evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. In total, 1509 patien...

A Look at Established Paradigms in Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer - Tom Keane

Tom Keane and Charles Ryan share in conversation about new developments and controversies in androgen deprivation therapy (ADT), answering questions on administering LHRH agonist and LHRH antagonist as well as sequencing new therapies on top of ADT in treatment for prostate cancer. Biographies: Thomas E. Keane, MBBCh, FRCSI, FACS, Professor and Chairman of Department of Urology at the Medical Univ...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.